All In Biotech

Drug Trial Radar · NCT06814145

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

A Phase 2, Multicenter, Open-label Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) With Heart Failure With Preserved Ejection Fraction (HFpEF)

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 440 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

440

Planned (sponsor's estimate)

Start

Apr 16, 2025

Primary completion

Aug 10, 2035

Study completion Aug 10, 2035

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH). This study focuses on Cpc-PH that is caused by heart failure with preserved ejection fraction (HFpEF). Researchers want to know if the study treatment, sotatercept, can treat people with Cpc-PH caused by HFpEF. This is an extension study, which means people who took part in a certain study on sotatercept for Cpc-PH (called a parent study) may be able to join this study. In this extension study, people will take sotatercept and researchers will follow their health for a longer time. The main goal of this extension study is to learn about the long-term safety of sotatercept and if people tolerate it over a longer period of time.

Conditions

  • Hypertension, Pulmonary

Interventions

  • SotaterceptBiological

    subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 10 years
  2. Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 10 years

Locations

57 sites in 12 countries. Site status is shown where the registry gives one.

  • Pulmonary Associates, PA ( Site 1008)

    Phoenix, Arizona

  • Scripps Clinic John R Anderson V Medical Pavillion ( Site 1004)

    La Jolla, California

  • Jeffrey S. Sager, MD Medical Corporation ( Site 1060)

    Santa Barbara, California

  • Stanford University Medical Center ( Site 1024)

    Stanford, California

  • South Denver Cardiology Associates ( Site 1091)

    Littleton, Colorado

  • Yale New Haven Hospital ( Site 1093)

    New Haven, Connecticut

  • AdventHealth Orlando ( Site 1058)

    Orlando, Florida

  • The Emory Clinic ( Site 1030)

    Atlanta, Georgia

  • Norton Pulmonary Specialists ( Site 1066)

    Louisville, Kentucky

  • University Of Nebraska Medical Center ( Site 1053)

    Omaha, Nebraska

  • Weill Cornell Medical Center ( Site 1046)

    New York, New York

  • Duke University Medical Center ( Site 1026)

    Durham, North Carolina

  • The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001)

    Cincinnati, Ohio

  • The Cleveland Clinic Foundation. ( Site 1065)

    Cleveland, Ohio

  • The Ohio State University Wexner Medical Center ( Site 1032)

    Columbus, Ohio

  • Allegheny General Hospital ( Site 1088)

    Pittsburgh, Pennsylvania

  • Lankenau Medical Center ( Site 1089)

    Wynnewood, Pennsylvania

  • Rhode Island Hospital ( Site 1039)

    Providence, Rhode Island

  • Medical University of South Carolina ( Site 1003)

    Charleston, South Carolina

  • Statcare Pulmonary Consultants ( Site 1031)

    Knoxville, Tennessee

  • Intermountain Medical Center ( Site 1079)

    Murray, Utah

  • Inova Fairfax Medical Campus ( Site 1078)

    Falls Church, Virginia

  • Pulmonary Associates of Richmond - West Broad Street ( Site 1069)

    Richmond, Virginia

  • Université Libre de Bruxelles - Hôpital Erasme ( Site 0100)

    Brussels, Bruxelles-Capitale, Region de, Belgium

  • Hamilton Health Sciences Hamilton General Hospital ( Site 0004)

    Hamilton, Ontario, Canada

  • Centre Hospitalier Universitaire de Nice - Hopital Pasteur ( Site 0206)

    Nice, Alpes-Maritimes, France

  • Hopital Arnaud de Villeneuve ( Site 0200)

    Montpellier, Herault, France

  • Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes ( Site 0205)

    Saint-Herblain, Loire-Atlantique, France

  • Centre Hopitalier Universitaire d'Angers ( Site 0204)

    Angers, Maine-et-Loire, France

  • CHU de Rouen ( Site 0203)

    Rouen, Seine-Maritime, France

  • Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre ( Site 0202)

    Le Kremlin-Bicêtre, Val-de-Marne, France

  • DRK Kliniken Berlin Westend ( Site 0307)

    Berlin, Germany

  • Thoraxklinik-Heidelberg gGmbH ( Site 0309)

    Heidelberg, Baden-Wurttemberg, Germany

  • Krankenhaus Neuwittelsbach ( Site 0310)

    München, Bavaria, Germany

  • UKGM Gießen/Marburg ( Site 0312)

    Giessen, Hesse, Germany

  • Universitaetsklinikum Koeln ( Site 0311)

    Cologne, North Rhine-Westphalia, Germany

  • Universitätsmedizin Johannes Gutenberg Universität Mainz ( Site 0315)

    Mainz, Rhineland-Palatinate, Germany

  • Universitaetsklinikum Carl Gustav Carus Dresden ( Site 0301)

    Dresden, Saxony, Germany

  • Rambam Health Care Campus ( Site 0403)

    Haifa, Israel

  • Edith Wolfson Medical Center ( Site 0404)

    Holon, Israel

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.